- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02482233
The END Perioperative Smoking Pilot Study
A Pilot Randomized Controlled Clinical Trial - "Electronic Nicotine Delivery Device (E-cigarette) for Perioperative Smoking Cessation in Veterans"
Study Overview
Status
Conditions
Detailed Description
It is well-known that smokers suffer more complications and higher risk of mortality after surgery than non-smokers. Despite this knowledge, it is unclear what clinicians can do to minimize this risk. Surgery represents a 'teachable moment' that might encourage smokers to engage in permanent cessation. Several small trials have shown that smoking cessation interventions can increase smoking cessation and reduce postoperative complications, particularly wound-healing complications, which can have an absolute risk reduction of up to 25%. Smoking cessation initiated in the perioperative period can also promote long-term smoking cessation. Despite the benefits of comprehensive smoking cessation interventions including nicotine replacement therapy, current standard of care at the SFVAMC does not routinely include specific preoperative smoking cessation pharmacotherapy or counselling. Although there is an urgent need for more data, e-cigarettes have been proposed as an alternative to nicotine replacement therapy that are at least as effective for smoking cessation, and may be more acceptable to some patients.
The main hypothesis of this pilot study is that the use of e-cigarettes and telephone counselling, compared to telephone counselling and transdermal nicotine replacement, in the perioperative period results in increased smoking cessation on the day of surgery and at 8-weeks after randomization in smokers presenting for elective surgery. As secondary hypotheses, the study will also assess the acceptability of e-cigarettes versus nicotine patches, postoperative complications within the first 30-days, length-of-stay in the PACU and hospital length-of-stay. The investigators will examine the above hypotheses through the following aims:
" Aim 1) To determine how e-cigarettes plus counselling compare to transdermal nicotine replacement plus counselling for the achievement of smoking cessation, when introduced prior to elective surgery in veterans.
The investigators plan to carry-out a pilot randomized controlled trial with parallel design comparing e-cigarettes and telephone counselling with transdermal nicotine replacement and telephone counselling. Our primary outcome is smoking cessation on the day of surgery, as confirmed biochemically by exhaled carbon monoxide. Smoking reduction (self-reported cigarettes per day) of 50% or more and bedside spirometry readings will be assessed as secondary outcomes.
" Aim 2) To determine the acceptability of e-cigarettes amongst veterans as an aid for smoking cessation and to determine the feasibility of recruitment, randomization, and follow-up procedures in preparation for large-scale trial.
Through implementation of this pilot trial, the investigators will determine the feasibility and acceptability of e-cigarettes for smoking cessation perioperatively in the veteran population and obtain the preliminary data necessary to run a larger trial on the effectiveness of e-cigarettes as a perioperative smoking cessation aid.
" Aim 3) To determine the safety of e-cigarettes as a harm reduction strategy to achieve short-term perioperative smoking cessation.
The investigators plan to improve the overall knowledge of the safety of short-term e-cigarettes use through careful surveillance for adverse events and side effects.
" Aim 4) To determine if e-cigarette use preoperatively is associated with a lower risk of complications postoperatively.
The investigators plan to measure the following secondary outcomes: postoperative complications and mortality within the first 30 days, post-anesthesia care unit (PACU) length-of-stay, and hospital length-of-stay. This will help us understand if e-cigarettes have the potential to be used for harm-reduction perioperatively.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94121
- San Francisco VA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adults (age >18)
- any gender
- scheduled to undergo elective surgery at the San Francisco Veterans Affairs Medical Center (SFVAMC)
- daily smoker, based on self-report of at least 2 cigarettes/day and having smoked in the last 7 days
- presenting to the anesthesia preoperative (APO) clinic at least 3 days preoperatively
Exclusion Criteria:
- emergency surgery (booked <24 hours preoperatively)
- consumers of non-cigarette forms of tobacco only (pipe, smokeless tobacco) or marijuana only
- already enrolled in a smoking cessation trial
- current smoking cessation pharmacotherapy
- daily user of e-cigarettes
- previous adverse reaction to e-cigarette or transdermal nicotine
- poor proficiency of English language¸as indicated by need for an interpreter (including family members) at the preadmission visit
- lacking capacity for consent (e.g. due to mental illness or dementia), as indicated by consent for surgery and other medical procedures being obtained from a substitute decision maker
- pregnant or breastfeeding
- unstable cardiac condition (unstable angina, unstable arrhythmia)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: ENDD
6-week supply of disposable "NJOY" ENDDs (e-cigarettes)
Both groups will receive: i) referral to the California Smokers' Helpline, ii) brief advice lasting less than 2 minutes, iii) a brochure from the ASA about quitting smoking before surgery |
As described above.
Other Names:
Referral to the California Smokers' Helpline.
California Smokers' Helpline will call the patient 4 times, or as agreed upon by the patient.
Brief advice lasting less than 2 minutes will be delivered by the research assistant, investigator, or healthcare provider.
The advice will be similar to the following statement (customized as needed to the patient): "The most important advice I can give you is that quitting smoking is the number one thing you can do for your health and to prepare yourself for surgery.
Quitting smoking before surgery may improve your chances of healing quickly.
There's evidence that the longer you quit before your surgery, the fewer complications you'll have.
I encourage you to make use of the resources that have been provided to you to help you quit and set your quit date for as soon as possible."
A brochure from the ASA (American Society of Anesthesiologists) about quitting smoking before surgery. Available free from the ASA: http://ecommerce.asahq.org/publicationsAndServices/PatientBrochure_%20For%20Posting.pdf |
|
ACTIVE_COMPARATOR: NRT (NicoDerm CQ)
A prescription for 6 weeks of transdermal nicotine replacement (on-formulary at the VA) in the following doses: For smokers of 10 cigarettes per day or more, a 3-week supply of 21 mg/d, 1-week supply of 14 mg/d, 1-week supply of 7 mg/d, and 1-week of 0mg/d. Smokers of <10 cigarettes per day, 3 weeks of 14 mg/d patches 2 weeks of 7 mg/d patches, and 1-week of 0mg/d. Both groups will receive: i) referral to the California Smokers' Helpline, ii) brief advice lasting less than 2 minutes, iii) a brochure from the ASA about quitting smoking before surgery |
Referral to the California Smokers' Helpline.
California Smokers' Helpline will call the patient 4 times, or as agreed upon by the patient.
Brief advice lasting less than 2 minutes will be delivered by the research assistant, investigator, or healthcare provider.
The advice will be similar to the following statement (customized as needed to the patient): "The most important advice I can give you is that quitting smoking is the number one thing you can do for your health and to prepare yourself for surgery.
Quitting smoking before surgery may improve your chances of healing quickly.
There's evidence that the longer you quit before your surgery, the fewer complications you'll have.
I encourage you to make use of the resources that have been provided to you to help you quit and set your quit date for as soon as possible."
A brochure from the ASA (American Society of Anesthesiologists) about quitting smoking before surgery. Available free from the ASA: http://ecommerce.asahq.org/publicationsAndServices/PatientBrochure_%20For%20Posting.pdf
As described above.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Smoking Status on the Day of Surgery (48-hour Point-prevalence Abstinence), by Self-report and Confirmed With Exhaled Carbon Monoxide (CO)
Time Frame: day of surgery (expected average around 1-2 weeks after enrollment/randomization)
|
Confirmed abstinent. Abstinence confirmed with exhaled carbon monoxoide <10ppm. Time Frame depends on date of preadmission clinic visit |
day of surgery (expected average around 1-2 weeks after enrollment/randomization)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency of Use of Product - Number Reporting Use Daily or Most Days
Time Frame: 8-weeks
|
how often product (e-cigarette or patch) was used (everyday except while hospitalized, most days, a few times a week, once a week, less than once a week, not at all) Result reported is those that used the product daily or most days |
8-weeks
|
|
Report of How Helpful the Product Was for Quitting
Time Frame: 8-weeks
|
7-point likert scale (strongly disagree to strongly agree)
|
8-weeks
|
|
How Satisfied the Patient Was With the Product (E-cigarette or Patch)
Time Frame: 8-weeks
|
7-point likert scale (strongly disagree to strongly agree)
|
8-weeks
|
|
How Likely the Patient Would be to Recommend the Product (E-cigarette or Patch) to Others
Time Frame: 8-weeks
|
7-point likert scale (strongly disagree to strongly agree)
|
8-weeks
|
|
Smoking Status 8-weeks After Randomization (Confirmed by Exhaled CO)
Time Frame: 8-weeks
|
by self-report and confirmed by exhaled CO<10ppm - confirmed abstinent
|
8-weeks
|
|
Smoking Reduction
Time Frame: on day of surgery and 8-weeks after randomization
|
50% or less regular cigarette use compared to baseline as determined by asking participants to self-report daily cigarette use in cigarettes per day at each time point.
|
on day of surgery and 8-weeks after randomization
|
|
Number of Participants With Dual Use
Time Frame: on day of surgery and 8-weeks after randomization
|
use of both regular and e-cigarettes concurrently
|
on day of surgery and 8-weeks after randomization
|
|
Spirometry - FEV1/FVC Change
Time Frame: day of surgery and 8-weeks
|
Change in FEV1/FVC from baseline to day of surgery / 8-weeks.
FEV1/FVC is expressed in percent.
For example, if FEV1/FVC was 75%, 80%, and 85% at baseline, day of surgery and 8-weeks, result is reported as change in FEV1/FVC being +5% and +10% for day of surgery and 8-weeks respectively.
|
day of surgery and 8-weeks
|
|
Spirometry - FEV1
Time Frame: day of surgery and 8-weeks
|
change in FEV1 (mL) compared to baseline
|
day of surgery and 8-weeks
|
|
Cotinine Level (Change in)
Time Frame: day of surgery and 8-weeks
|
salivary
|
day of surgery and 8-weeks
|
|
Number of Participants With Postoperative Complications (Composite)
Time Frame: 30-days postop
|
by chart review - research assistant or investigator examined notes and investigations postoperatively for complications by telephone self-report - patients were asked open-ended question about whether they experienced any postoperative complications
|
30-days postop
|
|
Long-term Smoking Status - Use of Conventional Cigarettes
Time Frame: 6 months
|
by self-report (7-day point prevalence)
|
6 months
|
|
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Time Frame: 8 weeks
|
all patients will be asked about adverse events each time they are contacted (day of surgery, 30-days postoperatively, and 8-weeks after randomization), and they will also be able to call to report adverse events to the study team any time during the study.
|
8 weeks
|
|
Number of Participants Postoperative Complications (Composite)
Time Frame: 30-days postop
|
by telephone self-report
|
30-days postop
|
Collaborators and Investigators
Investigators
- Principal Investigator: Susan M Lee, MD, MAS, UCSF / SFVAMC
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Substance-Related Disorders
- Tobacco Use Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Ganglionic Stimulants
- Nicotinic Agonists
- Cholinergic Agonists
- Nicotine
Other Study ID Numbers
- 14-15274
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
National Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Cigarette Smoking | Tobacco, SmokingUnited States
-
University of VirginiaRecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking, Cigarette | Quitting SmokingUnited States
-
University GhentActive, not recruitingSmoking | Smoking Tobacco | Smoking Prevention | Smoking CigaretteBelgium
-
Medical University of South CarolinaCompletedSmoking | Smoking Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Maastricht University Medical CenterThe Investigative Desk; SEO Amsterdam Economics; IVO Research InstituteEnrolling by invitationSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsNetherlands
-
Jennifer Marler, MDCompletedSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsUnited States
-
Johns Hopkins UniversityNational Center for Advancing Translational Sciences (NCATS); Community Partnership...CompletedSmoking Cessation | Smoking Reduction | Smoking, TobaccoUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)Completed
-
Virginia Polytechnic Institute and State UniversityCompletedCigarette Smoking Behavior | Smoking Behaviors | CigaretteUnited States
Clinical Trials on ENDD (NJOY)
-
King's College LondonCompletedSchizophrenia | Schizophreniform Disorder | Bipolar DisorderUnited Kingdom
-
Milton S. Hershey Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruitingChronic Obstructive Pulmonary DiseaseUnited States
-
Massachusetts General HospitalDana-Farber Cancer Institute; University of Massachusetts, BostonCompletedElectronic Cigarette Use | Nicotine Dependence | Smoking, CigaretteUnited States
-
University of Nevada, RenoCompletedTobacco Dependence Caused by CigarettesUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)Completed
-
NYU Langone HealthRecruitingCigarette SmokingUnited States
-
LA Clinical TrialsNJOY, Inc.UnknownNicotine DependenceUnited States
-
Juul Labs, Inc.CompletedTobacco Use | Tobacco Smoking | Nicotine Dependence | Nicotine Dependence, CigarettesNew Zealand
-
Rose Research Center, LLCGlobal Action to End SmokingCompletedSmoking Cessation | Harm ReductionUnited States
-
R.J. Reynolds Vapor CompanyCovance; R.J. Reynolds Tobacco Company; MAS (Materials Analytical Services), LLCCompleted